KEPRO

Phenylbutazone 20% Inj. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on phenylbutazone 20% in a veterinary solution for injection. These components give the product a practical place in veterinary programs aimed at management of pain and inflammation, particularly musculoskeletal and locomotor conditions where a veterinarian selects an NSAID approach. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, Phenylbutazone is an NSAID that reduces prostaglandin synthesis and thereby decreases inflammatory pain, swelling and related discomfort. Its use requires careful attention to species, hydration status and gastrointestinal or renal risk. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include species authorized by the local product registration, traditionally including horses in many veterinary markets. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of Phenylbutazone 20% Inj. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat management of pain and inflammation, particularly musculoskeletal and locomotor conditions where a veterinarian selects an NSAID approach. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Before using an NSAID, hydration, renal function and gastrointestinal risk should be considered because adverse effects are more likely in dehydrated animals or those with shock, ulceration or kidney impairment. Concurrent use of multiple NSAIDs or an NSAID with a corticosteroid should generally be avoided unless specifically directed. Analgesic therapy is most effective when combined with diagnosis and management of the condition that is causing pain or inflammation.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, Phenylbutazone 20% Inj. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

Doxy-Gen 20/20 WSP is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on doxycycline hyclate 200 mg/g and gentamicin sulphate 200 mg/g. These components give the product a practical place in veterinary programs aimed at susceptible gastrointestinal and respiratory bacterial infections, especially mixed infections in which broad antibacterial coverage is required. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, Doxycycline inhibits bacterial protein synthesis, while gentamicin is an aminoglycoside that acts rapidly on susceptible bacteria. Their complementary distribution gives the product both intestinal and systemic relevance. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include poultry, calves and pigs. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of Doxy-Gen 20/20 WSP is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat susceptible gastrointestinal and respiratory bacterial infections, especially mixed infections in which broad antibacterial coverage is required. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Responsible antimicrobial use is essential in infection management. Selection should be based on diagnosis, the likely site of infection and, whenever practical, culture and susceptibility testing. Unnecessary or repeated exposure can accelerate antimicrobial resistance, so treatment should follow veterinary direction and the prescribed course should be completed. Clinical improvement should be monitored together with farm-level measures such as hygiene, ventilation, water quality, nutrition, biosecurity and isolation of affected animals when appropriate.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, Doxy-Gen 20/20 WSP can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

Furosemide 5% Inj. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on furosemide 5% in a veterinary injectable solution. These components give the product a practical place in veterinary programs aimed at management of clinically significant fluid retention and edema, including situations associated with congestive heart failure, pulmonary edema or udder edema where a veterinarian determines diuresis is appropriate. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, Furosemide is a loop diuretic that reduces sodium and chloride reabsorption in the kidney, increasing urinary excretion of water and electrolytes and thereby helping decrease excess fluid volume. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include cattle, horses, dogs and cats as commonly indicated for veterinary furosemide products. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of Furosemide 5% Inj. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat management of clinically significant fluid retention and edema, including situations associated with congestive heart failure, pulmonary edema or udder edema where a veterinarian determines diuresis is appropriate. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Because loop diuresis can be powerful, treatment requires attention to hydration, renal function and electrolyte balance, especially sodium and potassium during repeated administration. The aim is to remove clinically excessive fluid without causing dehydration, hypotension or metabolic disturbance. The underlying cause of fluid retention—such as cardiac, pulmonary or renal disease—should also be investigated because a diuretic reduces fluid burden but does not necessarily correct the primary disease.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, Furosemide 5% Inj. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

HEPAROL PLUS is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on sorbitol, L-carnitine, betaine HCl, choline chloride, D-panthenol, magnesium sulphate, DL-methionine and vitamin C. These components give the product a practical place in veterinary programs aimed at nutritional support for liver function, fat metabolism, appetite, recovery and periods of intensive production or metabolic stress. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, The formulation combines lipotropic nutrients and metabolic cofactors. Choline, methionine, betaine and carnitine support lipid handling, while panthenol contributes to coenzyme A pathways and vitamin C adds antioxidant support. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include cattle, sheep, goats, pigs and poultry. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of HEPAROL PLUS is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat nutritional support for liver function, fat metabolism, appetite, recovery and periods of intensive production or metabolic stress. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Nutritional supplements work best as part of a balanced feeding and management program rather than as a substitute for good feed or for treatment of an underlying disease. Requirements may rise during transport, vaccination, feed changes, convalescence, peak production and environmental stress. Reviewing the total vitamin and mineral contribution of the ration helps prevent both deficiency and unnecessary oversupply, particularly with nutrients that can accumulate when used excessively.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, HEPAROL PLUS can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

Kepromec Inj. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on ivermectin 10 mg/ml in an injectable veterinary formulation. These components give the product a practical place in veterinary programs aimed at treatment and control of susceptible internal and external parasites, including gastrointestinal and pulmonary nematodes and selected ectoparasites. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, Ivermectin binds selectively to glutamate-gated chloride channels in susceptible invertebrates, increasing chloride permeability and causing paralysis and death of the parasite while offering broad antiparasitic activity at veterinary doses. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include cattle and other indicated livestock species depending on local registration. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of Kepromec Inj. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat treatment and control of susceptible internal and external parasites, including gastrointestinal and pulmonary nematodes and selected ectoparasites. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Parasite control should be part of an integrated program that considers the dominant parasites, timing of treatment, pasture or housing management, sanitation and monitoring of response. Repeated reliance on the same antiparasitic class may encourage resistance, so fecal testing or other diagnostic monitoring can be valuable. Withdrawal periods and species restrictions must be followed carefully, and ivermectin products should never be used in unapproved species because susceptibility differs markedly between animals.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, Kepromec Inj. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

Keprovit B Complex Inj. is a veterinary multivitamin solution for injection formulated to provide animals with a comprehensive source of B-group vitamins. These essential vitamins participate in a wide range of metabolic processes and are particularly important for energy production, nutrient utilization, normal nervous system function, blood formation, appetite, growth and overall physiological performance. Because B vitamins are involved in the metabolism of carbohydrates, proteins and fats, maintaining an adequate supply is important for animals experiencing periods of increased nutritional demand.

The requirement for B-complex vitamins may increase during rapid growth, pregnancy, lactation, intensive production, transportation, environmental stress, reduced feed intake and recovery following illness. Nutritional imbalance, poor appetite or periods of increased metabolic activity may also contribute to an insufficient supply of certain vitamins. Keprovit B Complex Inj. provides a practical injectable option for delivering these nutrients directly when additional vitamin support is considered appropriate by a veterinarian.

By supporting normal metabolic pathways, B vitamins contribute to the efficient conversion of dietary nutrients into usable energy. This makes Keprovit B Complex Inj. particularly relevant as part of supportive veterinary management for animals showing reduced appetite, weakness, poor general condition or increased nutritional requirements. Several B-group vitamins also contribute to the normal functioning of the nervous and muscular systems and are involved in processes related to red blood cell formation and tissue metabolism.

As an injectable preparation, Keprovit B Complex Inj. offers an alternative to oral supplementation in situations where feed or water consumption is reduced or when direct administration is preferred. The product is intended for veterinary use in animal species indicated on the official label and product information. Its use can form part of a broader animal health and nutritional support program aimed at maintaining vitality, feed utilization, metabolic efficiency and general condition.

Keprovit B Complex Inj. should be administered according to the official product instructions and under appropriate veterinary guidance. Dosage, route of administration, frequency and duration should be determined according to the animal species, body weight, clinical condition and nutritional requirements. The product should not be considered a substitute for balanced feeding, appropriate herd management or veterinary diagnosis and treatment.

When used responsibly as part of a comprehensive veterinary program, Keprovit B Complex Inj. provides a convenient source of B-complex vitamins to support normal metabolism, appetite, energy production, growth, recovery and overall animal performance.

L.S. Injection is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on lincomycin 50 mg/ml and spectinomycin 100 mg/ml. These components give the product a practical place in veterinary programs aimed at susceptible respiratory and gastrointestinal infections, including infections in which Mycoplasma may be involved, as well as selected species-specific bacterial conditions. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, Lincomycin is active mainly against susceptible Gram-positive organisms and Mycoplasma, while spectinomycin extends activity particularly toward susceptible Gram-negative bacteria and Mycoplasma. Their combined profile broadens practical coverage. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include calves, pigs, sheep, goats, poultry, dogs and cats according to the Kepro catalogue. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of L.S. Injection is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat susceptible respiratory and gastrointestinal infections, including infections in which Mycoplasma may be involved, as well as selected species-specific bacterial conditions. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Responsible antimicrobial use is essential in infection management. Selection should be based on diagnosis, the likely site of infection and, whenever practical, culture and susceptibility testing. Unnecessary or repeated exposure can accelerate antimicrobial resistance, so treatment should follow veterinary direction and the prescribed course should be completed. Clinical improvement should be monitored together with farm-level measures such as hygiene, ventilation, water quality, nutrition, biosecurity and isolation of affected animals when appropriate.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, L.S. Injection can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

Oxytet 20% LA Inj. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on oxytetracycline 200 mg/ml in a long-acting injectable formulation. These components give the product a practical place in veterinary programs aimed at susceptible respiratory, systemic and localized bacterial infections where extended oxytetracycline exposure is clinically useful. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, The active substance inhibits bacterial protein synthesis through the 30S ribosomal subunit. The long-acting carrier is designed to extend therapeutic concentrations after administration compared with conventional short-acting oxytetracycline injections. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include cattle, sheep, goats and pigs as indicated on current packaging and product information. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of Oxytet 20% LA Inj. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat susceptible respiratory, systemic and localized bacterial infections where extended oxytetracycline exposure is clinically useful. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Responsible antimicrobial use is essential in infection management. Selection should be based on diagnosis, the likely site of infection and, whenever practical, culture and susceptibility testing. Unnecessary or repeated exposure can accelerate antimicrobial resistance, so treatment should follow veterinary direction and the prescribed course should be completed. Clinical improvement should be monitored together with farm-level measures such as hygiene, ventilation, water quality, nutrition, biosecurity and isolation of affected animals when appropriate.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, Oxytet 20% LA Inj. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

Penstrep 20/25 Inj. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on procaine penicillin G 200 mg/ml and dihydrostreptomycin sulphate 250 mg/ml. These components give the product a practical place in veterinary programs aimed at susceptible respiratory, uterine and alimentary infections, mastitis, metritis, septic conditions, cystitis, joint infections and selected secondary bacterial infections. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, Procaine penicillin provides bactericidal activity primarily against susceptible Gram-positive organisms, while dihydrostreptomycin is an aminoglycoside active against a complementary range of susceptible bacteria. The combination is intended to broaden antibacterial coverage. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include cattle, horses, pigs, foals, calves, sheep and goats. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of Penstrep 20/25 Inj. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat susceptible respiratory, uterine and alimentary infections, mastitis, metritis, septic conditions, cystitis, joint infections and selected secondary bacterial infections. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Responsible antimicrobial use is essential in infection management. Selection should be based on diagnosis, the likely site of infection and, whenever practical, culture and susceptibility testing. Unnecessary or repeated exposure can accelerate antimicrobial resistance, so treatment should follow veterinary direction and the prescribed course should be completed. Clinical improvement should be monitored together with farm-level measures such as hygiene, ventilation, water quality, nutrition, biosecurity and isolation of affected animals when appropriate.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, Penstrep 20/25 Inj. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

PROCAL INJ. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on calcium gluconate 350 mg/ml and calcium glucoheptonate 100 mg/ml. These components give the product a practical place in veterinary programs aimed at support in hypocalcaemic conditions including milk fever and postpartum paresis, and prevention or treatment of calcium deficiency in indicated species. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, The two soluble calcium sources provide parenteral calcium that can be absorbed rapidly, helping restore circulating calcium when physiological demand exceeds intake or mobilization. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include cattle, horses, calves, foals, sheep, goats, pigs, piglets, dogs, cats and rabbits. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of PROCAL INJ. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat support in hypocalcaemic conditions including milk fever and postpartum paresis, and prevention or treatment of calcium deficiency in indicated species. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Calcium disorders deserve prompt assessment because they may affect muscle, cardiac and neurologic function and often occur around parturition or high milk production. Injectable calcium should be administered carefully and animals should be monitored, especially during intravenous use, because overly rapid increases in circulating calcium can trigger adverse cardiac effects. Long-term prevention also depends on ration design, mineral balance and appropriate vitamin D status.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, PROCAL INJ. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

Vit AD3E Inj. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on injectable vitamins A, D3 and E. These components give the product a practical place in veterinary programs aimed at prevention and correction of deficiencies involving vitamins A, D3 and E, with nutritional support for growth, reproduction, epithelial health, bone metabolism and recovery. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, Vitamin A contributes to epithelial and visual function, vitamin D3 regulates calcium and phosphorus metabolism, and vitamin E provides antioxidant protection that is particularly relevant to muscle and cell-membrane health. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include horses, cattle, calves, pigs, sheep, goats and other species shown on the product label. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of Vit AD3E Inj. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat prevention and correction of deficiencies involving vitamins A, D3 and E, with nutritional support for growth, reproduction, epithelial health, bone metabolism and recovery. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Nutritional supplements work best as part of a balanced feeding and management program rather than as a substitute for good feed or for treatment of an underlying disease. Requirements may rise during transport, vaccination, feed changes, convalescence, peak production and environmental stress. Reviewing the total vitamin and mineral contribution of the ration helps prevent both deficiency and unnecessary oversupply, particularly with nutrients that can accumulate when used excessively.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, Vit AD3E Inj. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.

VITAFLASH INJ. is a Kepro veterinary product developed to provide a clearly defined therapeutic or nutritional role. Its formulation is based on a multivitamin injectable formulation including vitamins A, D3, E and several B-group vitamins with additional supportive vitamins. These components give the product a practical place in veterinary programs aimed at treatment and prevention of vitamin deficiencies associated with growth problems, weakness, convalescence, anorexia, reproductive problems and periods of increased demand. The dosage form is designed for professional animal use and should be incorporated into a treatment or support plan only in accordance with the approved label and local registration.
From a functional perspective, By combining fat-soluble and water-soluble vitamins, the formulation supports epithelial health, bone metabolism, antioxidant protection, energy pathways, nervous-system function and general recovery. This profile explains why the product may be useful when a veterinarian wants to address a specific physiological or clinical need rather than treat signs without identifying their cause. According to available product information, target species include cattle, horses, calves, foals, sheep, goats, pigs and other indicated species. Final case selection still depends on diagnosis, age, body weight, production stage and the presence of concurrent disease or medicines that could influence response or safety.
A key strength of VITAFLASH INJ. is the combination of a recognizable active profile with a veterinary dosage form suited to routine clinic or farm use. When selected for the right case, it can form part of a broader program intended to support or treat treatment and prevention of vitamin deficiencies associated with growth problems, weakness, convalescence, anorexia, reproductive problems and periods of increased demand. It should not be presented as a universal answer to every animal showing the same clinical sign, because similar signs may arise from very different infectious, nutritional, metabolic or management-related causes.
Nutritional supplements work best as part of a balanced feeding and management program rather than as a substitute for good feed or for treatment of an underlying disease. Requirements may rise during transport, vaccination, feed changes, convalescence, peak production and environmental stress. Reviewing the total vitamin and mineral contribution of the ration helps prevent both deficiency and unnecessary oversupply, particularly with nutrients that can accumulate when used excessively.
This copy is written for a veterinary product page, so it focuses on product identity, clinical or nutritional role, and practical positioning rather than reproducing a dosing leaflet. The product should always be used according to the locally approved label and package leaflet because authorized species, dosage schedules, withdrawal periods, contraindications and warnings may differ between markets. Appropriate veterinary use also depends on diagnosis, body weight, age, kidney and liver status, pregnancy or lactation, concurrent medicines and, for antimicrobials, the likely or confirmed susceptibility of the causative organism. Website information should therefore complement, not replace, professional veterinary advice and the manufacturer’s approved instructions.
For a website product page, VITAFLASH INJ. can be positioned as a specialized Kepro option with a defined formulation and a clear practical purpose. A complete page should ideally show the original pack, dosage form, principal active ingredients, registered target species and the general therapeutic or nutritional role. Detailed dosage, withdrawal and contraindication information should remain linked to the official leaflet or be provided by a veterinarian. This approach gives customers useful, professional information while keeping regulatory and clinical decisions where they belong: with the approved product information and qualified veterinary guidance.